str. 3)		2. Transa Date	action Day/Year)	2A. Deemed Execution Date,	3. Transactio Code (Insti	n Dispose				5. Amount of Securities	I	6. Owner Form: Di (D) or Inc	rect	Indirect
		1					4. Securities Acquired (A) o Disposed Of (D) (Instr. 3, 4						Direct	7. Nature of Indirect Beneficial
Т	able I - Nor	n-Deriv	ative S	ecurities Acqu	uired, Dis	sposed o	of, or	Benef	icially O	wned				
(State)	(Zip)								contract, ins	truction or writte	en plan th	nat is inter	nded to sa	atisfy the
NY	10022		Rule	10b5-1(c) Tr	ansacti	on Indi	icatio	on						
AVENUE			4. If Ame	endment, Date of O	riginal Filed	(Month/Da	ıy/Year))	6. Indiv	Form filed b	y One F	Reporting	Person	,
· · · ·	(Middle)				on (Month/[)ay/Year)				Officer (give below)	e title		Other (s below)	specify
of Reporting Person*			<u>Corvu</u>	is Pharmaceu	<u>ticals, Ir</u>	<u>c.</u> [CRV	VS]							
longer subject to or Form 5 tinue. <i>See</i>	STAT		ed pursuar	nt to Section 16(a) of	of the Secur	ties Exchai	inge Ac	t of 1934		P	Estimat	ed averag		3235-0287 0.5
					on, D.C. 20	549			0	OMB APPROVAL				
14	UNITE	STA	TES S				NG	E CO	MMISS	ION				
	Ionger subject to or Form 5 tinue. See of Reporting Person* VISORS LLC (First) AVENUE NY (State)	Index subject to pr Form 5 tinue. See STAT STAT STATEMENT See Statement of Reporting Person* VISORS LLC (First) (Middle) AVENUE (State) (Zip)	Industry Industry Industry Industry StateMe File StateMe File File Industry In	Ionger subject to pr Form 5 linue. See STATEMENT OF See Filed pursuar or Sec of Reporting Person* 2. Issuer VISORS LLC 2. Issuer (First) (Middle) AVENUE 4. If Ame NY 10022 (State) (Zip)	Washingt Washingt STATEMENT OF CHANGES STATEMENT OF CHANGES Filed pursuant to Section 16(a) or Section 30(h) of the Im or Section 30(h) of the Im of Reporting Person* VISORS LLC (First) (Middle) AVENUE NY 10022 (State) (Zip)	Washington, D.C. 20 Washington, D.C. 20 STATEMENT OF CHANGES IN BE Filed pursuant to Section 16(a) of the Securior or Section 30(h) of the Investment Cc of Reporting Person* VISORS LLC (First) (Middle) AVENUE 3. Date of Earliest Transaction (Month/E 05/06/2024) NY 10022 (State) (Zip)	Washington, D.C. 20549 Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFIC Filed pursuant to Section 16(a) of the Securities Excha or Section 30(h) of the Investment Company Ac of Reporting Person* VISORS LLC (First) (Middle) AVENUE 2. Issuer Name and Ticker or Trading Symbol Corvus Pharmaceuticals, Inc. [CRV 3. Date of Earliest Transaction (Month/Day/Year) 05/06/2024 NY 10022 (State) (Zip)	Washington, D.C. 20549 Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL Filed pursuant to Section 16(a) of the Securities Exchange Ac or Section 30(h) of the Investment Company Act of 194 Af Reporting Person* VISORS LLC (First) (Middle) AVENUE NY 10022 (State) (Zip)	Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWN Statement of person* VISORS LLC (First) (Middle) AVENUE 2. Issuer Name and Ticker or Trading Symbol Corvus Pharmaceuticals, Inc. [CRVS] 3. Date of Earliest Transaction (Month/Day/Year) 05/06/2024 4. If Amendment, Date of Original Filed (Month/Day/Year) (State) (Zip)	Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 of Reporting Person* VISORS LLC (First) (Middle) AVENUE 2. Issuer Name and Ticker or Trading Symbol Corvus Pharmaceuticals, Inc. [CRVS] 5. Relat (Check X NY 10022 (State) (Zip)	Washington, D.C. 20549 Ionger subject to or Form 5 linue. See Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 of Reporting Person* VISORS LLC (First) (Middle) AVENUE NY 10022 Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or writter	Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 of Reporting Person* VISORS LLC (First) (Middle) AVENUE 2. Issuer Name and Ticker or Trading Symbol Corvus Pharmaceuticals, Inc. [CRVS] 5. Relationship of Reporting P (Check all applicable) X Director 05/06/2024 0. Individual or Joint/Group Filed (Month/Day/Year) AVENUE 4. If Amendment, Date of Original Filed (Month/Day/Year) NY 10022 (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned	Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP or Form 5 inuc. See Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 of Reporting Person* VISORS LLC (First) (Middle) AVENUE 2. Issuer Name and Ticker or Trading Symbol Corvus Pharmaceuticals, Inc. [CRVS] 5. Relationship of Reporting Person(s) (Check all applicable) X Director X 05/06/2024 4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Che Form filed by One Reporting X NY 10022 Rule 10b5-1(c) Transaction Indication (Gtate) Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is inter affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. Table 1 - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned	Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP inue. See Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 of Reporting Person* VISORS LLC (First) (Middle) AVENUE 2. Issuer Name and Ticker or Trading Symbol Corvus Pharmaceuticals, Inc. [CRVS] 3. Date of Earliest Transaction (Month/Day/Year) 5. Relationship of Reporting Person (Sto6/2024 AVENUE 4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Appli Form filed by One Reporting Person X NY 10022 (State) Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to sa affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		5. Number Derivative Securities Acquired (or Dispose (D) (Instr. 3 and 5)	A) d of	6. Date Exerc Expiration Da (Month/Day/Y	ate			8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)		
Pre- Funded Warrants (right to buy)	\$0.0001	05/06/2024		Р		1,444,085		(1)	(1)	Common Stock	1,444,085	\$1.7311	1,444,085	I	See Footnotes ⁽³⁾⁽⁴⁾
Common Warrants (right to buy)	\$3.5	05/06/2024		Р		1,397,684		(2)	(2)	Common Stock	1,397,684	(5)	1,397,684	I	See Footnotes ⁽³⁾⁽⁴⁾

ORBIMED A	DVISORS LLC		
(Last)	(First)	(Middle)	
601 LEXINGTO	N AVENUE		
54TH FLOOR			
(Street)			
NEW YORK	NY	10022	
(City)	(State)	(Zip)	
	s of Reporting Person [*] ital GP V LLC		
(Last)	(First)	(Middle)	
601 LEXINGTO	N AVENUE		
54TH FLOOR			
(01			
(Street) NEW YORK	NY	10022	

1. Name and Address of Reporting Person*

Explanation of Responses:

1. Subject to the terms and conditions set forth in the Pre-Funded Warrant, the holder thereof may, at any time and from time to time on or after May 6, 2024, exercise the Pre-Funded Warrant until it has been exercised in full. The Pre-Funded Warrants reported herein contain an exercise limitation prohibiting the holder from exercising the Pre-Funded Warrants until such time as the holder, together with the Reporting Persons and certain other related parties, would not beneficially own after any such exercise more than 9.99% of the then issued and outstanding Common Stock (the "Blocker"). Due to the Blocker, the Pre-Funded Warrants beneficially owned by the Reporting Persons are not presently exercisable.

2. Subject to the terms and conditions set forth in the Common Warrant, the holder thereof may, at any time and from time to time on or after May 6, 2024, exercise the Common Warrant until it has been exercised in full. The Common Warrants reported herein contain an exercise limitation prohibiting the holder from exercising the Common Warrants until such time as the holder, together with the Reporting Persons and certain other related parties, would not beneficially own after any such exercise more than 9.99% of the then issued and outstanding Common Stock (the "Blocker"). Due to the Blocker, the Common Warrants beneficially owned by the Reporting Persons are not presently exercisable.

3. These securities are held of record by OrbiMed Private Investments V, LP ("OPI V"). OrbiMed Capital GP V LLC ("GP V") is the general partner of OPI V, and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI V.

4. This report on Form 4 is jointly filed by OrbiMed Advisors and GP V. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP V have designated a representative, Peter A. Thompson, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

5. Issued at no additional consideration to OPI V in connection with its subscription of Pre-Funded Warrants for shares of the Issuer's Common Stock at a price of \$1.7311.

 /s/ Carl L. Gordon, Member of OrbiMed Advisors LLC
 05/08/2024

 /s/ Carl L. Gordon, Member of OrbiMed Capital GP VI LLC
 05/08/2024

 ** Signature of Reporting Person
 Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. * If the form is filed by more than one reporting person, *see* Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.